Overview

  • Product nameAnti-Cyclin D1 antibodySee all Cyclin D1 primary antibodies ...
  • Description
    Mouse polyclonal to Cyclin D1
  • Tested applicationsWBmore details
  • Species reactivity
    Reacts with Xiphophorus maculatus. (Red wagtail platy)
  • Immunogen

    Vector coding for a partial recombinant fusion protein, corresponding to amino acids 10-104 of Cyclin D1 (Xiphophorus maculatus). Target sequence used to make the antibody: VDSIRRAHQD ENLLNDRVLQ TMLKAEENYL PSPNYFKCVQ KEIIPKMRKI LATWMLEVCE EQKCEEEVFP LAMNYLDRFL SVEATRKTRL QLLGA,

  • General notes


    This antibody was raised by a genetic immunization technique. Genetic immunization can be used to generate antibodies by directly delivering antigen-coding DNA into the animal, rather than injecting a protein or peptide (Tang et al. PubMed: 1545867; Chambers and Johnston PubMed 12910245; Barry and Johnston PubMed: 9234514). The animal's cells produce the protein, which stimulates the animal's immune system to produce antibodies against that particular protein. A vector coding for a partial fusion protein was used for genetic immunisation of a mouse and the resulting serum was tested in Western blot against an E.coli lysate containing that partial fusion protein. Genetic immunization offers enormous advantages over the traditional protein-based immunization method. DNA is faster, cheaper and easier to produce and can be produced by standard techniques readily amenable to automation. Furthermore, the antibodies generated by genetic immunization are usually of superior quality with regard to specificity, affinity and recognizing the native protein.

Properties

  • FormLiquid
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
  • Storage bufferPreservative: None
    Constituents: 50% Glycerol, Whole serum
  • PurityWhole antiserum
  • Primary antibody notes This antibody was raised by a genetic immunization technique. Genetic immunization can be used to generate antibodies by directly delivering antigen-coding DNA into the animal, rather than injecting a protein or peptide (Tang et al. PubMed: 1545867; Chambers and Johnston PubMed 12910245; Barry and Johnston PubMed: 9234514). The animal's cells produce the protein, which stimulates the animal's immune system to produce antibodies against that particular protein. A vector coding for a partial fusion protein was used for genetic immunisation of a mouse and the resulting serum was tested in Western blot against an E.coli lysate containing that partial fusion protein. Genetic immunization offers enormous advantages over the traditional protein-based immunization method. DNA is faster, cheaper and easier to produce and can be produced by standard techniques readily amenable to automation. Furthermore, the antibodies generated by genetic immunization are usually of superior quality with regard to specificity, affinity and recognizing the native protein.
  • Clonality Polyclonal
  • IsotypeIgG
  • Research Areas

Applications

Our Abpromise guarantee covers the use of ab52734 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
  • Application notesWB: 1/1000.

    This antibody has been tested in Western blot against an E.coli lysate containing the partial recombinant fusion protein used as an immunogen. We have no data on detection of endogenous protein.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionEssential for the control of the cell cycle at the G1/S (start) transition.
    • Involvement in diseaseNote=A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle.
      Note=A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer.
      Defects in CCND1 are a cause of multiple myeloma (MM) [MIM:254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving CCND1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus.
    • Sequence similaritiesBelongs to the cyclin family. Cyclin D subfamily.
    • Post-translational
      modifications
      Phosphorylation at Thr-286 by MAP kinases is required for ubiquitination and degradation following DNA damage. It probably plays an essential role for recognition by the FBXO31 component of SCF (SKP1-cullin-F-box) protein ligase complex.
      Ubiquitinated, primarily as 'Lys-48'-linked polyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-box protein) ubiquitin-protein ligase complex containing FBXO4 and CRYAB (By similarity). Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. Ubiquitination leads to its degradation and G1 arrest. Deubiquitinated by USP2; leading to stabilize it.
    • Cellular localizationNucleus.
    • Information by UniProt
    • Alternative names
      • AI327039 antibody
      • B cell ccl/lymphoma 1 antibody
      • B cell CLL/lymphoma 1 antibody
      • B cell leukemia 1 antibody
      • B cell leukemia 1 antibody
      • B cell lymphoma 1 protein antibody
      • B-cell lymphoma 1 protein antibody
      • BCL 1 antibody
      • BCL-1 antibody
      • BCL-1 oncogene antibody
      • BCL1 antibody
      • BCL1 oncogene antibody
      • CCND 1 antibody
      • CCND1 antibody
      • CCND1 protein antibody
      • CCND1/FSTL3 fusion gene, included antibody
      • CCND1/IGHG1 fusion gene antibody
      • CCND1/IGHG1 fusion gene, included antibody
      • CCND1/IGLC1 fusion gene, included antibody
      • CCND1/PTH fusion gene, included antibody
      • CCND1_HUMAN antibody
      • cD1 antibody
      • Cyl 1 antibody
      • D11S287E antibody
      • G1/S specific cyclin D1 antibody
      • G1/S-specific cyclin-D1 antibody
      • Parathyroid adenomatosis 1 antibody
      • PRAD1 antibody
      • PRAD1 oncogene antibody
      • U21B31 antibody
      see all

    References for Anti-Cyclin D1 antibody (ab52734)

    ab52734 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab52734.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"